---
created: 2025-04-13
updated: 2025-04-13T10:53
id: juP+=yc.dI
specialty: pharmaco
specialty_id: 334
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::11-antitumor-antibiotics
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::11-antitumor-antibiotics::anthracyclines
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::doxorubicin,-daunorubicin
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::02-dna-&-cellular-division::03-bleomycin,-doxorubicin,-daunorubicin,-actinomycin-d::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
**PEGylation** of liposomal Doxorubicin can also result in **Hand-Foot Syndrome**

---

# Answer
PEGylation allows small amounts of the drug to leak from capillaries in the palms and soles of the feet, resulting in redness, tenderness, and peeling of the skin (Palmar Plantar Erythrodysesthesia aka Hand-foot Syndrome)